Foresite Capital Management IV, LLC 13F Holdings · Q2 2026
Foresite Capital Management IV, LLC reported 6 securities worth $290.15M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: PHVS (56.95%), CYTK (20.98%), EIKN (8.74%). Among its top 25 positions this quarter: 1 new, 2 added, 3 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | $165.2M | 56.95% | 4.8M | Hold |
| 2 | CYTK | CYTOKINETICS INC | $60.9M | 20.98% | 714,695 | Added |
| 3 | EIKN | Eikon Therapeutics, Inc. | $25.4M | 8.74% | 1.9M | Hold |
| 4 | RLAY | Relay Therapeutics, Inc. | $23.4M | 8.06% | 1.2M | Added |
| 5 | XENE | Xenon Pharmaceuticals Inc. | $9.7M | 3.33% | 160,000 | Hold |
| 6 | CRNX | Crinetics Pharmaceuticals, Inc. | $5.6M | 1.93% | 150,000 | New |
| 7 | ALEC | Alector, Inc. | $0 | 0.00% | 0 | Exited |
| 8 | LYEL | Lyell Immunopharma, Inc. | $0 | 0.00% | 0 | Exited |
| 9 | MAZE | Maze Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR